Evidence map›Paper›PMID 34263356›Full record

ReviewApplied microbiology and biotechnology2021

The "beauty in the beast"-the multiple uses of Priestia megaterium in biotechnology.

Rebekka Biedendieck, Tobias Knuuti, Simon J Moore, Dieter Jahn

Open access · hybridAbstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Complete genome sequences of eightMicrobiology resource announcements · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Rebekka Biedendieck *Institute of Microbiology and Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany. r.biedendieck@tu-braunschweig.de.ORCID http://orcid.org/0000-0002-3567-6196
Tobias Knuuti *Institute of Microbiology and Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Simon J MooreSchool of Biosciences, University of Kent, Canterbury, UK.
Dieter JahnInstitute of Microbiology and Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Technische Universität Braunschweig · DEUniversity of Kent · GB

Funding

Deutsche Forschungsgemeinschaft JA 470 12/2
6 · The paper itself

Abstract

Over 30 years, the Gram-positive bacterium Priestia megaterium (previously known as Bacillus megaterium) was systematically developed for biotechnological applications ranging from the production of small molecules like vitamin B

Indexed as

Bacillus megateriumBeautyBiotechnologyRecombinant ProteinsVitamin B 12Recombinant ProteinsVitamin B 12Bacillus megateriumCell-free transcription-translationCytochrome P450Plant growth-promoting bacteriumPolyhydroxybutyrate (PHB)Priestia megateriumRecombinant protein productionVitamin B12

Identifiers

PMID34263356
PMCPMC8390425
OpenAlexW3182412047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.